SLE Clinical Trial
Official title:
Use of Telemedicine for Follow-up of Systemic Lupus Erythematosus ("TeleSLE") in the COVID-19 Outbreak: a Pragmatic Randomised Controlled Trial
Background Patients with systemic lupus erythematosus (SLE) might be more susceptible to Covid-19 due to the underlying disease, co-morbidities and the use of immunosuppressive drugs. The investigators hypothesize that telemedicine (TM) can be an effective mode of health-care delivery minimizing the risk of SARS-CoV-2 exposure, while maintaining disease control in these patients. Objectives The primary aim of this study is to evaluate the effectiveness to achieve remission or lupus low disease activity state (LLDAS) using TM delivered care compared to conventional in-person outpatient follow-up in SLE. The secondary objectives are to compare the patient reported outcomes and cost between the two modes of health care delivery. Study design This is a 12-months single centered pragmatic randomized controlled study. A total of 150 enrolled patients with SLE being followed at the Prince of Wales Hospital rheumatology clinics will be randomized to either TM (TM group) or standard care (SC group) in a 1:1 ratio. Patients in the TM group will receive scheduled follow-ups via videoconferencing using a custom-made mobile app. SC group patients will continue conventional standard in-person outpatient care. The disease and patient reported outcomes as well as the health care related costs will be compared. Expected outcomes Data from this study will support the notion that TM based care is as effective as conventional in-person care in achieving disease remission or LLDAS, as well as addressing psychosocial implications to ensure the best possible care for our patients in a cost-effective manner during this pandemic.
There is a single-center pragmatic randomized controlled trial over a 12-month period. The study will be performed at the Rheumatology clinics at the Prince of Wales Hospital, which is a regional hospital in Hong Kong. From May to October 2020, all consecutive patients with a diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology classification criteria will be invited to participate in the study if they are aged >18 years, able to speak or understand Chinese and are willing to come back for routine blood and urine tests [18]. Patients (or carers) need to possess the technology needed to conduct a TM visit - a smartphone, tablet, or computer. Patients will be excluded if they are pregnant or incapable of answering a questionnaire. Patients will be randomization to either TM (TM group) or standard follow-ups (SF group 1). Patients who refused to be randomized will be offered standard in-person outpatient follow-up (SF group 2). All patients who fulfill the inclusion criteria and have given written informed consent will be asked to complete the Systemic Lupus Activity Questionnaire (SLAQ), LupusPRO, Health Assessment Questionnaire Disability Index (HAQ-DI), Medical Outcomes Survey Short Form (SF-36), Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale (version 4) and Hospital Anxiety and Depression Scale (HADS). They will also be asked to rate the confidence to the mode of care on a 10-point Likert scale (0 = not at all confident to 10 = very much confident). Their demographic, socio-economic and clinical data will be collected. Patient will be randomized in a ratio of 1:1 to either TM group or SF group 1 using a computer-generated random number sequence. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05479071 -
Relation of Antibodies Against Oxidized Low Density Lipoproteins to Disease Activity and Cardiovascular Affection in Systemic Lupus.
|
||
Completed |
NCT02240888 -
Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response
|
N/A | |
Active, not recruiting |
NCT05748925 -
Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients
|
Phase 4 | |
Not yet recruiting |
NCT04517240 -
A Study on Protein Losing Enteropathy In Systemic Lupus Erythematosus
|
||
Completed |
NCT00710021 -
Vitamin D3 in Systemic Lupus Erythematosus
|
Phase 2 | |
Terminated |
NCT01946880 -
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
|
Phase 2 | |
Recruiting |
NCT06445127 -
Evaluation of Patients With Lupus Nephritis Using Kidney MRI (Magnetic Resonance Imaging)
|
N/A | |
Active, not recruiting |
NCT04018222 -
Translation of a Diagnostic Test for Lupus Flare Prediction From Bench to Clinic
|
||
Completed |
NCT03240536 -
Choosing Tests Wisely in Rheumatology
|
N/A | |
Active, not recruiting |
NCT04037293 -
Premature Atherosclerosis in Systemic Lupus Erythematosus
|
||
Not yet recruiting |
NCT04234633 -
Effect of Gender on Clinical Presentation of SLE ِAt Assiut University Hospitals
|
||
Completed |
NCT01207297 -
Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis
|
Phase 1 | |
Terminated |
NCT00152555 -
Physical Therapy for Systemic Lupus Erythematosus (SLE)
|
N/A | |
Recruiting |
NCT05822219 -
Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases
|
N/A | |
Completed |
NCT04806113 -
COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases
|
Phase 3 | |
Recruiting |
NCT05966480 -
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
|
Phase 2 | |
Completed |
NCT03155477 -
Effect Of Curcuma Xanthorrhiza and Vitamin D3 Supplementation in SLE Patients With Hypovitamin D
|
N/A | |
Recruiting |
NCT05342285 -
Flow Mediated Dilation in Association With Hyperuricemia
|
||
Not yet recruiting |
NCT03984227 -
New Signaling Pathway Targeting Systemic Lupus Erythematosus
|
||
Enrolling by invitation |
NCT03144063 -
Improving the Assessment of SLE Disease Activity
|
N/A |